A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Yangilik qisqacha mazmuni
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Ishonchli nashriyotlarning so‘nggi xabarlarini qisqa izohlar bilan kuzating. Tafsilotlar uchun asl manba havolasini oching.